HIV drug in development
Generic HIV drug
Hepatitis C drug in development
raltegravir QD A once-daily dose of Isentress. Approval expected in May.
ibalizumab A monoclonal antibody entry inhibitor given by infusion; an injectible may become available. Approval expected in June.
sofosbuvir/valpatasvir/voxilaprevir (GS-9857) A single-tablet regimen (STR) made up of direct-acting antivirals, two of them pangenotypic.
glecaprevir/pibrentasvir A pangenotypic regimen with two direct-acting antivirals.
bictegravir/emtricitabine/tenofovir alafenamide (GS-9883) An STR containing an integrase inhibitor (INSTI) that does not require boosting.
darunavir/cobicistat/tenofovir alafenamide/emtricitabineThe first single-tablet regimen containing a protease inhibitor.
fostemsavirAn HIV entry inhibitor that targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other HIV drugs.
doravirine/tenofovir disoproxil fumarate/lamivudine A single-tablet regimen containing a non-nuke that may work in those who have developed resistance to other non-nukes, with no food restrictions.
dolutegravir/rilpivirine New co-formulation of already approved INSTI and non-nuke; first STR using only two drugs.
Sustiva (efavirenz) expected to go generic first quarter.
efavirenz/tenofovir disoproxil fumarate/lamivudine expected to be available as generic first quarter; STR similar to Atripla.
Tenofovir disoproxil fumarate/lamivudine expected to be available as generic first quarter; fixed-dose combination similar to Truvada. Not studied or recommended for use as PrEP.
cabotegravir/rilpivirine LA A long-acting injectable containing an INSTI and an NNRTI.
Prezista (darunavir)goes generic.
Emtriva (emtricitabine) goes generic.
Truvada (tenofovir disoproxil fumarate/emtricitabine) goes generic.
Atripla (efavirenz/tenofovir disoproxil fumarate/ emtricitabine) goes generic.
Information courtesy of the Fair Pricing Coalition. Ror more, go to fairpricingcoalition.org.